Zynex Bankruptcy and Fraud Indictments
Analysis based on 35 articles · First reported Feb 24, 2026 · Last updated Apr 20, 2026
The market is significantly impacted by the severe decline of Zynex's stock, leading to substantial losses for investors. The ongoing securities class action lawsuits by Faruqi & Faruqi and Hagens Berman, coupled with the bankruptcy filing and criminal indictments of former executives, highlight the risks associated with corporate fraud and lack of internal controls in the medical device industry.
Zynex, a medical device company, is embroiled in a major scandal involving an alleged fraudulent overbilling scheme. The company is accused of shipping excessive products, inflating revenue, and filing false claims, which drew scrutiny from insurers like United States — Tricare. The Travelers Companies commenced an action against Zynex and its executives, Thomas Sandgaard and Anna Lucsok, seeking over $23 million in damages. Zynex reported a significant revenue shortfall in Q4 2024, leading to a 51.3% stock price drop. The company later acknowledged non-compliance with industry regulations, suspended guidance, and saw its stock fall another 45%. Former CEO Thomas Sandgaard and former COO Anna Lucsok were indicted for health care and securities fraud, resulting in their removal. Steve Dyson was appointed as the new CEO, and CFO Daniel Moorhead departed. Zynex subsequently filed for Chapter 11 bankruptcy and was delisted from the Nasdaq-100. Multiple securities law firms, including Faruqi & Faruqi and Hagens Berman, are pursuing class action lawsuits on behalf of investors who suffered significant losses.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard